TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
TransMedics Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$71.60+0.82 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- 18.6
- Dividend yield
- 0.00%
TransMedics Group, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue [Member] | $111.16M | $107.97M | $100.39M | $87.68M | $96.10M | $88.23M | $74.95M | $65.86M | $71.73M | $61.33M | $51.87M | $47.74M | 58.5% | +15.7% |
| Cost of service revenue | $78.79M | $65.96M | $60.37M | $56.15M | $61.27M | $55.30M | $46.68M | $42.90M | $42.57M | $35.53M | $29.30M | $18.69M | 41.5% | +28.6% |
| Service Unrelated to OCS Transplant [Member] | $1.00M | $1.30M | $1.00M | $1.20M | $1.00M | $900.00K | $1.10M | $1.30M | $1.10M | – | – | – | 0.5% | 0.0% |
| Unrelated to OCS Transplant [Member] | – | – | – | – | – | $900.00K | $1.10M | $1.30M | $1.10M | $900.00K | $2.50M | $2.40M | – | – |
By region
From the segment and revenue-disaggregation notes of TransMedics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.